Gilead Sciences (NASDAQ:GILD) surprises with Q3 2026 sales, full-year outlook slightly exceeds expectations
Gilead Sciences (GILD) reported Q3 2026 revenue of $8.3B, up 6.8% YoY, exceeding estimates. Full-year guidance of $31.15B midpoint is 1.3% above consensus. Non-GAAP EPS of $2.55 beat estimates by 16.2%. HIV business grew 18%, with prevention sales nearly doubling YoY. The company raised full-year revenue guidance by $1.6B since 2026.
How this was made
The 30-second read
Why it matters
Traders can use the raised full-year revenue guidance and the beat versus consensus to reassess near-term expectations, while monitoring the stated full-year EPS outlook as a potential constraint on valuation.
Market read
A company-specific earnings and guidance update with explicit beat and guidance numbers, plus a same-day share reaction, makes this actionable for positioning.
What to watch
The piece emphasizes base business growth and HIV prevention strength, but it does not quantify oncology or inflammation launch timing, which could be the key driver of whether the raised revenue guidance is sustainable.
Background
The article frames Gilead’s performance using multi-year growth, margin trajectory, and segment-level HIV dynamics, then ties the quarter to a guidance adjustment.
Ticker impact
Gilead reported Q3 2026 revenue up 6.8% to $8.3B and raised full-year revenue guidance to $31.15B at the midpoint.
Likely modest upward bias as traders price in raised base-business revenue guidance, while keeping an eye on the weaker full-year EPS guidance.
The text cites a revenue beat and guidance midpoint above consensus, plus a same-day share rise, but also notes full-year EPS guidance fell short, which can cap upside.
Market effects
Reinforces demand durability in HIV and progress across oncology and inflammation programs, which can marginally support sentiment toward large-cap biopharma revenue durability.
Primarily US large-cap healthcare sentiment; limited spillover beyond the sector.
US-listed biopharma results can influence global peers’ read-across on HIV franchise resilience, but the article provides no cross-border policy or regulatory catalyst.
Counterpoint
The revenue beat may not translate into stronger bottom-line outcomes because the article says full-year EPS guidance fell short, suggesting cost or mix headwinds despite top-line strength.
Key entities
- companyGilead Sciences
Reported Q3 2026 revenue and EPS results, and provided full-year revenue guidance at the midpoint.
